$XERS

Xeris Biopharma filed lawsuits against Torrent Pharma, Rising Pharma affiliates, and others, alleging infringement of its U.S. Patent No. 12,758,502 covering KEVEYIS. The company seeks injunctive relief and damages. According to the SEC filing, the suits were filed in the District of New Jersey.

Xeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On October 13, 2026, Xeris Biopharma Holdings, Inc. (the “Company”), through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District Court for the District of New Jersey against defendants (

Xeris Biopharma Holdings (XERS) reported record Q2 results, with Recorlev revenue up 81% YoY, and raised 2026 revenue guidance to $385M-$390M. The company retired convertible notes, simplifying its capital structure. Management emphasizes commercial execution, with near-term catalysts tied to Recorlev uptake and broader portfolio demand. Analysts project 21.2% yearly revenue growth to $596.8M by 2029, though some caution on pricing pressure.

Xeris Biopharma officer Beth Hecht plans to sell 16,666 shares, valued at $159,326.96, on October 1, 2026. She previously sold 16,666 shares each in August and September 2026 under a 10b5-1 plan, according to filings.

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.

Lundbeck (LON:0ND5) has shown interest in acquiring Xeris Pharmaceuticals (NASDAQ:XERS), according to Bloomberg. Xeris, focused on endocrine and rare disease therapies, stated it is not for sale. Lundbeck, specializing in neurological and psychiatric conditions, may expand into rare endocrine disorders through this potential deal. Discussions are preliminary, and no formal offer has been made.

Xeris Biopharma (XERS) shares rose 6% after reports that H Lundbeck (HLBBF) is considering an acquisition, despite Xeris stating it is not for sale. Xeris's P/S ratio is 5.2x, above its historical median and industry average, reflecting growth expectations. The company's GF Score is 68, indicating moderate quality with strong growth but weak profitability. Insider activity shows no buying and $4.8M in selling, while institutional interest is mixed.

medmix' Drug Delivery (Haselmeier) partners with Xeris Pharmaceuticals to develop XP-8121, a once-weekly hypothyroidism treatment. The D-Flex™ pen injector, with high dose accuracy, will be used for precise delivery of the drug. Both companies emphasize the importance of accurate dosing for narrow therapeutic index drugs. medmix' shares are traded on the SIX Swiss Exchange (SIX: MEDX).

Xeris (XERS) Q2 2026 earnings call said it retired its convertible notes, eliminating nearly $3 million in annual interest expense. The company raised full-year 2026 total revenue guidance to $385 million to $390 million. Q2 net product revenue was $91 million (+34% YoY) and total revenue $92.1 million (+29%). Recorlev net revenue was $56.8 million (+81% YoY), Gvoke about $23 million, and Keveyis nearly $12 million. It also reported new U.S. patent allowances for Keveyis and XP-8121.

Xeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Total revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue increased 81% year-over-year to approximately $57 million Tightens full